Sat Kartar Life Ltd Q1 FY27 Earnings Analysis

- FY 27 product revenue target: ₹300 crores, driven by: - Current run rate at ₹225 crores with expected 25% growth in current business. - Subsidiaries contributing ~₹22 crores. - US operations adding ₹10-15 crores. - AI efficiencies and nutraceuticals (Ajooni Life Sciences) adding ~₹20 crores. - FY 28 product revenue target: ₹500 crores, fueled by: - New high-ticket products. - Better product margins. - Controlled advertisement spend. - Increased ticket size and scaling sales. - Hospital business expansion: - 300 beds target by end FY 27, starting simultaneous set-up of 4 facilities. - Plan to expand to 1000 beds by FY 28. - Hospital margins expected at 30-35% at 60% occupancy. - Blended margin (product + hospital) expected at 18-20% by H1 FY 28. - Growth to come from wider geographic penetration beyond strongholds (TN, UP).

- FY26 PAT margin grew from 6% to 8.5% with revenue growth from 160 to 200 crore. - FY27 target: Revenue growth from 200 to 300 crore; PAT margin targeted at 11-12%. - FY28 target: Revenue expected to cross 500 crore with blended margin including hospital business reaching 18-20%. - Hospital business at 60% occupancy expected to deliver 30-35% margin; higher occupancy exponentially increases margins. - Operating leverage from fixed costs expected to improve profitability as revenues scale. - AI optimization is improving ROI by 4-5%, expected to further enhance margins over time. - Subsidiaries expected to grow from ₹1.2 crores revenue in FY26 to 25-30 crore in FY27, supporting overall profit growth. - No immediate plans for equity dilution; future funding for expansion may come from debt. - Overall, significant margin expansion and profit growth planned via scaling products and hospital beds, with EPS expected to benefit accordingly.

- Current capex includes upgrading existing manufacturing facility (capsule and powder units) with an investment of around ₹1-1.25 crore. - Hospital bed setup capex is estimated at ₹7-8 lakhs per bed, with ₹4 lakhs considered as fixed asset cost and the balance as working capital. - For the planned 1000 beds, estimated capex is around ₹40 crore (₹4 lakh per bed). - Capital for initial phases of hospital expansion raised with ₹45 crore in the bank to build the first phase. - Subsequent phases to be funded through internal cash generation and possibly debt; no current plans for further equity dilution. - No plan to produce all products in-house; focus on scaling with collaborations and selective manufacturing upgrades. - US subsidiary investment awaiting RBI approval, expected operational soon, no capital cited beyond standard overseas direct investment processes.

- The company plans to fund any shortfall in working capital primarily through debt. - Currently, there is no plan for further equity dilution or raising funds through equity. - The company has raised around ₹45 crores in capital, which will support the first phase of hospital expansion. - Cash generation from hospitals and the company’s core business is expected to fund the second phase of hospital growth. - Overall, debt is the preferred mode of additional fundraising if required, with no immediate plans for equity fundraising.

- As per the transcript on page 7, the number of orders can be estimated by dividing revenue by ticket size: FY26 revenue was ₹200 crores and ticket size around ₹3,250, implying approximately 6.15 million orders. - Current business run rate is around ₹225 crores, expecting growth to ₹300 crores in FY27 with new initiatives contributing additional ₹50-₹55 crores. - Growth drivers include subsidiaries, US operations, AI improvements, nutraceuticals via Ajooni Life Sciences, and geographic expansion in under-penetrated markets. - Company is focusing on deepening reach from strong pockets like Tamil Nadu, North Uttar Pradesh, Madhya Pradesh, and Maharashtra, aiming to increase order volume through wider pan-India presence. - Repeat patient orders are stable around 25-26%, supporting recurring order inflow.